ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
11 announcements
Sanofi India received a GST show cause notice alleging excess input tax credit claims. The total demand, including interest, is Rs. 23.74 Crore.
Sanofi Healthcare India acquired 3,500,000 equity shares (15.20%) of Sanofi India Limited via an inter-se promoter group transfer. The transaction was executed as a block deal.
Hoechst GmbH transferred 3,500,000 shares of Sanofi India Limited to Sanofi Healthcare India Private Limited. This inter-se promoter group transfer represents a 15.20% stake.
Sanofi India disclosed that the State Tax Officer, Tiruvallur dropped a ₹1.07 Crore GST demand for FY 2022-23. The company confirmed no material financial or operational impact.
Sanofi Healthcare India Private Limited, a promoter group entity, proposed an inter-se transfer of up to 3,500,000 shares from Hoechst GmbH. This transaction qualifies for open offer exemption.
The Supreme Court dismissed Sanofi India's petition to quash criminal proceedings. No penalty or operational restriction is imposed on the company at this stage.
Sanofi India reported Q2 2026 domestic growth of 8%, driven by a 14% surge in its diabetes business. PBT (before exceptional items) grew 19% YoY to INR 112 crores.
Sanofi India Q2 2026 domestic sales grew 8% YoY, led by a 14% surge in Insulins. Profit Before Tax (PBT) rose 19% YoY to ₹1,123 Mio.
Sanofi India reported Q2'26 domestic sales growth of 8% YoY, driven by a 14% surge in its diabetes business. Management is focusing on business model transformation and operational efficiency.
Sanofi India Ltd reported revenue from operations of ₹437.7 Cr (+7.7% YoY) and net profit of ₹83.5 Cr (+20.1% YoY) for Q1 FY27.
Sanofi India Ltd reported revenue from operations of ₹472.3 Cr (-11.9% YoY) and net profit of ₹102.6 Cr (-14.1% YoY) for Q4 FY26.